Table 5.

The association between use of antiplatelet or anticoagulant drugs and retinal/subretinal hemorrhage at baseline among those with hypertension and those without hypertension

			With hypertension (N=807)				Without hypertension (N=358)
Use of anti-coagulant or anti-platelet drugs at baseline	n	Retinal/subretinal hemorrhage at baseline n (%)	Adjusted odds ratio (95% CI)*	P-value	n	Retinal/subretinal hemorrhage at baseline n (%)	Adjusted odds ratio (95% CI)*	P-value
Any use of antiplatelet or anticoagulant drugs		P=0.003		0.01		P=0.13		0.19
No	337	190 (56.4%)	1.00		220	142 (64.6%)	1.00
Yes	470	314 (66.8%)	1.48 (1.09 – 2.01)		138	78 (56.5%)	0.73 (0.45 – 1.18)
Use of antiplatelet drugs		P=0.007		0.02		P=0.07		0.11
No	398	230 (57.8%)	1.00		236	153 (64.8%)	1.00
Yes	409	274 (67.0%)	1.43 (1.06 – 1.92)		122	67 (54.9%)	0.68 (0.42 – 1.10)
Use of anticoagulant drugs		P=0.26		0.42		P=0.64		0.56
No	731	452 (61.8%)	1.00		340	208 (61.2%)	1.00
Yes	76	52 (68.4%)	1.24 (0.74 – 2.08)		18	12 (66.7%)	1.37 (0.48 – 3.95)
Type of antiplatelet or anticoagulant drug at baseline
None	337	190 (56.4%)	1.00		220	142 (64.6%)	1.00
Aspirin	368	245 (66.6%)	1.50 (1.09 – 2.07)	0.01	108	62 (57.4%)	0.74 (0.44 – 1.23)	0.23
Clopidogrel bisulfate	70	52 (74.3%)	2.38 (1.22 – 4.65)	0.01	10	3 (30.0%)	0.27 (0.05 – 1.41)	0.12
Warfarin sodium	76	52 (68.4%)	1.67 (0.94 – 2.97)	0.08	18	12 (66.7%)	1.05 (0.34 – 3.26)	0.93
Dose of Aspirin		P=0.08				P=0.58
None	439	259 (59.0%)	1.00		250	158 (63.2%)	1.00
1–81 mg	297	199 (67.0%)	1.37 (1.00 – 1.87)	0.049	89	51 (57.3%)	0.79 (0.47 – 1.34)	0.38
≥82 mg	71	46 (64.8%)	1.25 (0.73 – 2.12)	0.42	19	11 (57.9%)	0.79 (0.30 – 2.10)	0.64

OR = odds ratio, CI = confidence interval.

^*Adjusted by age (as continuous), gender, smoking status, diabetes, medical history of cardiovascular diseases, and CNV in fellow eye.